Form 8-K · Current Report · Filed 2026-06-23
Illumina Appoints Dr. Daniel Skovronsky to Board of Directors
Illumina, Inc. announced on June 16, 2026, the appointment of Daniel M. Skovronsky, M.D., Ph.D., to its Board of Directors, effective immediately. Dr. Skovronsky, currently the Chief Scientific and Product Officer of Eli Lilly and Company, brings extensive experience in drug discovery, clinical development, and translational medicine, which are directly relevant to Illumina's work in genomics and multiomics platforms. He will stand for election at the Company's 2027 annual meeting of stockholders to serve for a one-year term. Dr. Skovronsky qualifies as an independent director under the applicable rules of The Nasdaq Stock Market and the Securities and Exchange Commission.
- Filer
- Illumina, Inc. ILMN · NASDAQ
- Filed
- Accession
- 0001110803-26-000138
- CIK
- 0001110803
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$161.38
Next session
+8.5%
Since filing
+27.1%
Latest close
$205.10
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ILMN reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, ILMN insiders reported 59 Form 4 transactions — net selling of $168.5M.
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Never miss another ILMN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.